255 related articles for article (PubMed ID: 29561434)
1. Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).
Cao Z; Wei L; Zhu W; Yao X
Medicine (Baltimore); 2018 Mar; 97(12):e0182. PubMed ID: 29561434
[TBL] [Abstract][Full Text] [Related]
2. Inverse association of p16 INK4a and p14 ARF methylation of the CDKN2a locus in different Gleason scores of prostate cancer.
Verdoodt B; Sommerer F; Palisaar RJ; Noldus J; Vogt M; Nambiar S; Tannapfel A; Mirmohammadsadegh A; Neid M
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):295-301. PubMed ID: 21912429
[TBL] [Abstract][Full Text] [Related]
3. Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers.
Nguyen TT; Nguyen CT; Gonzales FA; Nichols PW; Yu MC; Jones PA
Prostate; 2000 May; 43(3):233-42. PubMed ID: 10797499
[TBL] [Abstract][Full Text] [Related]
4. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
Breyer J; Wirtz RM; Erben P; Worst TS; Stoehr R; Eckstein M; Bertz S; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W;
Clin Genitourin Cancer; 2018 Aug; 16(4):248-256.e2. PubMed ID: 29525349
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
6. Clinical and prognostic effects of
Xia L; Zhang W; Gao L
Biomarkers; 2019 Nov; 24(7):700-711. PubMed ID: 31382782
[No Abstract] [Full Text] [Related]
7. A quantitative promoter methylation profile of prostate cancer.
Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of Retinoic Acid Receptor Beta Promoter Methylation in Prostate Cancer: A Meta-Analysis.
Dou M; Zhou X; Fan Z; Ding X; Li L; Wang S; Xue W; Wang H; Suo Z; Deng X
Cell Physiol Biochem; 2018; 45(6):2497-2505. PubMed ID: 29554659
[TBL] [Abstract][Full Text] [Related]
9. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
Kirsch M; Mörz M; Pinzer T; Schackert HK; Schackert G
Genes Chromosomes Cancer; 2009 Feb; 48(2):143-54. PubMed ID: 18973139
[TBL] [Abstract][Full Text] [Related]
10. Nonpromoter methylation of the CDKN2A gene with active transcription is associated with improved locoregional control in laryngeal squamous cell carcinoma.
Ben-Dayan MM; Ow TJ; Belbin TJ; Wetzler J; Smith RV; Childs G; Diergaarde B; Hayes DN; Grandis JR; Prystowsky MB; Schlecht NF
Cancer Med; 2017 Feb; 6(2):397-407. PubMed ID: 28102032
[TBL] [Abstract][Full Text] [Related]
11. Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma.
Sinha S; Chunder N; Mukherjee N; Alam N; Roy A; Roychoudhury S; Kumar Panda C
Ann Surg Oncol; 2008 Apr; 15(4):1070-80. PubMed ID: 18239974
[TBL] [Abstract][Full Text] [Related]
12. Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome.
Lim AM; Do H; Young RJ; Wong SQ; Angel C; Collins M; Takano EA; Corry J; Wiesenfeld D; Kleid S; Sigston E; Lyons B; Fox SB; Rischin D; Dobrovic A; Solomon B
Int J Cancer; 2014 Aug; 135(4):887-95. PubMed ID: 24436120
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
Spitzwieser M; Entfellner E; Werner B; Pulverer W; Pfeiler G; Hacker S; Cichna-Markl M
BMC Cancer; 2017 Apr; 17(1):260. PubMed ID: 28403857
[TBL] [Abstract][Full Text] [Related]
14. CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis.
Zhou Y; Wang XB; Qiu XP; Shuai Zhang ; Wang C; Zheng F
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):529-541. PubMed ID: 30143452
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis and The Cancer Genome Atlas data of prostate cancer risk and prognosis using epithelial cell adhesion molecule (EpCAM) expression.
Hu Y; Wu Q; Gao J; Zhang Y; Wang Y
BMC Urol; 2019 Jul; 19(1):67. PubMed ID: 31324239
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of hypermethylation of p16 gene in esophageal cancer.
Xu R; Wang F; Wu L; Wang J; Lu C
Cancer Biomark; 2013; 13(4):215-26. PubMed ID: 24240582
[TBL] [Abstract][Full Text] [Related]
17. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of global DNA hypomethylation in human prostate cancer and prostatic intraepithelial neoplasm tissues by immunohistochemistry.
Yang B; Sun H; Lin W; Hou W; Li H; Zhang L; Li F; Gu Y; Song Y; Li Q; Zhang F
Urol Oncol; 2013 Jul; 31(5):628-34. PubMed ID: 21704537
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Tumor Suppressor Gene CDKN2A and Encoded p16-INK4a Protein by Covalent Modifications.
Jiao Y; Feng Y; Wang X
Biochemistry (Mosc); 2018 Nov; 83(11):1289-1298. PubMed ID: 30482142
[TBL] [Abstract][Full Text] [Related]
20. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
